What is Leerink Partnrs’ Forecast for Nuvalent Q2 Earnings?

Nuvalent, Inc. (NASDAQ:NUVL) – Investment analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Nuvalent in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($1.17) per share for the quarter. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent’s Q3 2025 earnings at ($1.18) EPS and Q4 2025 earnings at ($1.10) EPS.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.35). During the same period last year, the business earned ($0.59) EPS.

Several other research firms have also commented on NUVL. BMO Capital Markets boosted their price objective on shares of Nuvalent from $132.00 to $134.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Nuvalent in a research report on Friday, January 17th. UBS Group began coverage on shares of Nuvalent in a research report on Thursday, October 24th. They issued a “neutral” rating and a $100.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $115.00 price objective on shares of Nuvalent in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.36.

Nuvalent Stock Down 1.2 %

Nuvalent stock opened at $85.68 on Friday. Nuvalent has a 52 week low of $61.79 and a 52 week high of $113.51. The firm’s 50-day simple moving average is $83.71 and its 200 day simple moving average is $87.90. The firm has a market capitalization of $6.09 billion, a PE ratio of -24.69 and a beta of 1.38.

Institutional Trading of Nuvalent

A number of institutional investors and hedge funds have recently bought and sold shares of the business. HighVista Strategies LLC increased its position in Nuvalent by 1.1% during the 3rd quarter. HighVista Strategies LLC now owns 29,018 shares of the company’s stock worth $2,969,000 after purchasing an additional 320 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Nuvalent by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,147 shares of the company’s stock worth $213,000 after purchasing an additional 382 shares in the last quarter. KBC Group NV increased its position in Nuvalent by 61.1% during the 4th quarter. KBC Group NV now owns 1,587 shares of the company’s stock worth $124,000 after purchasing an additional 602 shares in the last quarter. US Bancorp DE acquired a new stake in Nuvalent during the 4th quarter worth approximately $90,000. Finally, M&T Bank Corp increased its position in Nuvalent by 16.4% during the 4th quarter. M&T Bank Corp now owns 8,473 shares of the company’s stock worth $664,000 after purchasing an additional 1,192 shares in the last quarter. Institutional investors and hedge funds own 97.26% of the company’s stock.

Insider Transactions at Nuvalent

In other news, CEO James Richard Porter sold 27,000 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $86.61, for a total transaction of $2,338,470.00. Following the transaction, the chief executive officer now directly owns 188,113 shares in the company, valued at $16,292,466.93. This represents a 12.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew Shair sold 2,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $83.78, for a total transaction of $167,560.00. Following the transaction, the director now owns 220,522 shares in the company, valued at approximately $18,475,333.16. The trade was a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 83,800 shares of company stock worth $6,812,164 in the last three months. Company insiders own 12.52% of the company’s stock.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.